Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration

mAbs

Volumn 1, Issue 4, 2009, Pages 364-369

  Lu, Yanmei ^a   Xiang, Hong ^a   Liu, Peter ^a   Tong, Raymond R ^a   Watts, Ryan J ^a   Koch, Alexander W ^a   Sandoval, Wendy N ^a   Damico, Lisa A ^a   Wai, Lee Wong ^a   Meng, Y Gloria ^a  

^a GENENTECH INC   (United States)

Author keywords

Angiogenesis; Anti neuropilin 1; Circulating neuropilin 1; ELISA; Serum; Soluble neuropilin 1

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NEUROPILIN 1; NEUROPILIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOLECULAR WEIGHT; MONKEY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

EID: 77953659997     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.4.8885     Document Type: Article

References (24)

1. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 1997; 90:739-751 (Pubitemid 27357965)
2. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell 1997; 90:753-762
3. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92:735-745 (Pubitemid 28155313)
4. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995; 121:4309-4318 (Pubitemid 26007578)
5. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999; 126:4895-4902
6. Kitsukawa T, Shimizu M, Sanbo M, Hirata T, Taniguchi M, Bekku Y, et al. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 1997; 19:995-1005. (Pubitemid 27512361)
7. Kawakami A, Kitsukawa T, Takagi S, Fujisawa H. Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system. J Neurobiol 1996; 29:1-17. (Pubitemid 26021768)
8. Nakamura F, Goshima Y. Structural and functional relation of neuropilins. Adv Exp Med Biol 2002; 515:55-69.
9. Cai H, Reed RR. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 1999; 19:6519-6527 (Pubitemid 29347451)
10. Chen H, He Z, Bagri A, Tessier-Lavigne M. Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins. Neuron 1998; 21:1283-1290 (Pubitemid 29022531)
11. Fujisawa H. From the discovery of neuropilin to the determination of its adhesion sites. Adv Exp Med Biol 2002; 515:1-12. (Pubitemid 36324178)
12. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 2002; 277:24818-24825 (Pubitemid 34952014)
13. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y, et al. Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 2007; 366:815-829 (Pubitemid 46175863)
14. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007; 11:53-67. (Pubitemid 46054517)
15. Cackowski FC, Xu L, Hu B, Cheng SY. Identification of two novel alternatively spliced Neuropilin-1 isoforms. Genomics 2004; 84:82-94. (Pubitemid 38760132)
16. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci USA 2000; 97:2573-2578
17. Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms. Genomics 2000; 70:211-222 (Pubitemid 32003398)
18. Mamluk R, Klagsbrun M, Detmar M, Bielenberg DR. Soluble neuropilin targeted to the skin inhibits vascular permeability. Angiogenesis 2005; 8:217-227 (Pubitemid 41759146)
19. Hsei V, Deguzman GG, Nixon A, Gaudreault J. Complexation of VEGF with bevaczumab decreases VEGF clearance in rats. Pharm Res 2002; 19:1753-1756 (Pubitemid 35305529)
20. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-121
21. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor downregulation and hampers biological activity. Proc Natl Acad Sci USA 2006; 103:5090-5095
22. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61:4744-4749 (Pubitemid 32691885)
23. Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, Scherle P, et al. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res 2008; 103:916-918
24. 3+) affinity chromatography. Anal Biochem 1986; 154:250-254